Neuraxpharm Boosts Branded Business With Established Sanofi Portfolios
Latest Acquisition Should See Firm’s Annual Gross Sales Expand To €600m
CNS specialist Neuraxpharm has purchased two of Sanofi’s product portfolios, substantially expanding the number of branded products it has to offer.
You may also be interested in...
Linking up with Germany’s Neuraxpharm to sell the multiple sclerosis drug Briumvi in Europe and elsewhere has gone down badly with investors but the bashing that TG Therapeutics’ shares has taken seems excessive.
Neuraxpharm has rebranded a Spanish finished dosage form facility to mark its “full integration” within the group, as it focuses on building its profile in Europe.
In light of its ongoing focus on European expansion and a desire to sharpen concentration on its central CNS business, Neuraxpharm has opted to divest its API subsidiary Inke to a private equity firm.